Francesca Palandri
0000-0001-8367-5668
29 papers found
Refreshing results…
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real‐world data
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study
Impact of 2016‐WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
Missing publications? Search for publications with a matching author name.